Ever since Acceleron and its needy partners at Celgene touted positive Phase III top-line results for luspatercept for patients suffering from myelodysplastic syndrome as well as beta thalassemia, analysts have been trying to figure out just how good the numbers need to be in order to live up to the companies’ estimates this drug will deliver $2 billion-plus in peak sales.
So you better believe that their appearance in the showcase plenary session at ASH on Saturday was keeping plenty of people on their toes.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription